このページの翻訳は実験的なもので、現在開発中です。お待ちしております！

Kyowa Kirin バランスシートの健全性

財務の健全性基準チェック /66

Kyowa Kirinの総株主資本は¥844.0B 、総負債は¥0.0で、負債比率は0%となります。総資産と総負債はそれぞれ¥1,065.9Bと¥221.9Bです。 Kyowa Kirinの EBIT は¥98.4Bで、利息カバレッジ比率-266.6です。現金および短期投資は¥334.8Bです。

主要情報

負債資本比率

JP¥0

負債

インタレスト・カバレッジ・レシオ	-266.6x
現金	JP¥334.78b
エクイティ	JP¥843.97b
負債合計	JP¥221.91b
総資産	JP¥1.07t

財務の健全性に関する最新情報

更新なし

Recent updates

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Jun 19

Are Investors Undervaluing Kyowa Kirin Co., Ltd. (TSE:4151) By 35%?

Jun 14

Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

May 09

財務状況分析

短期負債: 4151の短期資産 ( ¥553.6B ) が短期負債 ( ¥156.6B ) を超えています。

長期負債: 4151の短期資産 ( ¥553.6B ) が長期負債 ( ¥65.4B ) を上回っています。

デット・ツー・エクイティの歴史と分析

負債レベル: 4151は負債がありません。

負債の削減: 4151 5 年前には負債がありませんでした。

債務返済能力: 4151には負債がないため、営業キャッシュフローでカバーする必要はありません。

インタレストカバレッジ: 4151には負債がないため、利息支払いの負担は問題になりません。

Kyowa Kirin バランスシートの健全性

財務の健全性 基準チェック /66

主要情報

財務の健全性に関する最新情報

Recent updates

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Are Investors Undervaluing Kyowa Kirin Co., Ltd. (TSE:4151) By 35%?

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2024 Results on Feb 06, 2025

Earnings Miss: Kyowa Kirin Co., Ltd. Missed EPS By 5.6% And Analysts Are Revising Their Forecasts

First quarter 2024 earnings: EPS misses analyst expectations

Kyowa Kirin (TSE:4151) Is Due To Pay A Dividend Of ¥29.00

Kyowa Kirin's (TSE:4151) Dividend Will Be ¥29.00

Final dividend of JP¥29.00 announced

Here's Why We Think Kyowa Kirin (TSE:4151) Is Well Worth Watching

Kyowa Kirin Co., Ltd. to Present Phase 2B Post-Hoc Analysis and Symposium At the American Academy of Dermatology Annual Meeting 2024

Kyowa Kirin Co., Ltd. to Report Q3, 2024 Results on Oct 31, 2024

Kyowa Kirin Co., Ltd.'s (TSE:4151) 26% Price Boost Is Out Of Tune With Earnings

Full year 2023 earnings: EPS and revenues exceed analyst expectations

New minor risk - Share price stability

Investor sentiment improves as stock rises 17%

Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2023, Payable on March 25, 2024; Provides Dividend Guidance for the Second Quarter of 2024

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 22, 2024

Kyowa Kirin Announces First Patient Enrolled in the Phase 2 Clinical Trial Evaluating Tivozanib Eye Drops in Patients with Diabetic Macular Edema

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Kyowa Kirin Co., Ltd. (TSE:4151) completed the acquisition of Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others.

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2023 Results on Feb 07, 2024

Upcoming dividend of JP¥27.00 per share at 2.3% yield

Now 20% undervalued after recent price drop

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Kyowa Kirin Co., Ltd. (TSE:4151) entered into a Transaction Agreement to acquire Orchard Therapeutics plc (NasdaqCM:ORTX) from RA Capital Management, L.P., Deep Track Capital, LP, Zentree Investment Management Pte. Ltd. and others for approximately $470 million.

Kyowa Kirin Co., Ltd. to Report Q3, 2023 Results on Nov 01, 2023

New minor risk - Earnings quality

New minor risk - Profit margin trend

Second quarter 2023 earnings: EPS and revenues miss analyst expectations

Now 22% undervalued after recent price drop

Now 20% undervalued after recent price drop

Upcoming dividend of JP¥27.00 per share at 2.0% yield

Kyowa Kirin Co., Ltd. to Report Q1, 2024 Results on Aug 03, 2023

First quarter 2023 earnings: EPS and revenues miss analyst expectations

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Year Ending December 31, 2023

High number of new directors

Full year 2022 earnings: EPS misses analyst expectations

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 24, 2023

Kyowa Kirin Co., Ltd. Declares Dividend for the Fiscal Year Ended December 31, 2022, Payable on March 27, 2023; Provides Dividend Guidance for the Second Quarter of 2023

Kyowa Kirin Co., Ltd. to Report Fiscal Year 2022 Results on Feb 07, 2023

Upcoming dividend of JP¥24.00 per share

Consensus forecasts updated

Kyowa Kirin Co., Ltd. Revises Consolidated Earnings Guidance for the Year Ended December 31, 2022

Kyowa Kirin Co., Ltd. and MEI Pharma, Inc. Announce Topline Data from Phase 2 MIRAGE Study Evaluating Zandelisib in Patients with Indolent B-Cell Non-Hodgkin’s Lymphoma in Japan

High number of new directors

Third quarter 2022 earnings: EPS and revenues miss analyst expectations

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Fiscal Year Ending December 31, 2022

Kyowa Kirin Co., Ltd. Receives European Commission Approval for Use of CRYSVITA(R) (burosumab) for the Treatment of Tumour-Induced Osteomalacia

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Kyowa Kirin Co., Ltd. Announces Second Quarter End Dividend for the Fiscal Year Ending December 31, 2022, Payable from September 1, 2022; Provided Year End Dividend Guidance for the Fiscal Year Ending December 31, 2022

MEI Pharma and Kyowa Kirin Announce Publication in the Lancet Oncology of Data from Phase 1B Clinical Study of Zandelisib in Patients with Relapsed or Refractory B-Cell Malignancy

Kyowa Kirin Receives Positive CHMP Opinion for Use of CRYSVITA (burosumab) for the Treatment of Tumour-Induced Osteomalacia (TIO)

Upcoming dividend of JP¥24.00 per share

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

MEI Pharma and Kyowa Kirin Report New Clinical Data on Zandelisib at American Society of Clinical Oncology Annual Meeting 2022

Kyowa Kirin Co., Ltd. Provides Dividend Guidance for the Second Quarter and Full Year Ending December 31, 2022

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

High number of new directors

High number of new directors

Now 20% undervalued after recent price drop

Kyowa Kirin Co., Ltd., Annual General Meeting, Mar 25, 2022

Full year 2021 earnings: EPS exceeds analyst expectations

Upcoming dividend of JP¥23.00 per share

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce Data from Ongoing Global Phase 2 TIDAL Study Evaluating Zandelisib as Single Agent in Patients with Relapsed or Refractory Follicular Lymphoma

Third quarter 2021 earnings released: EPS JP¥14.58 (vs JP¥18.04 in 3Q 2020)

Kyowa Kirin Co., Ltd. Announces Publication of New Data Highlighting the Sustained Benefits of Treatment with CRYSVITA® (burosumab) in Adults with X-Linked Hypophosphataemia

Kyowa Kirin Initiates Phase 2 Clinical Study of G-Lasta® for the Mobilization of Hematopoietic Stem Cells into Peripheral Blood for Autologous Blood Stem Cell Transplantation in Japan

Kyowa Kirin Co., Ltd. to Present Atopic Dermatitis Clinical Data from Khk4083/Amg 451 Phase 2 Study At the European Academy of Dermatology and Venereology 30Th Congress

MEI Pharma, Inc. and Kyowa Kirin Co., Ltd. Announce First Patient Dosed in the Phase 3 Coastal Study Evaluating Zandelisib Plus Rituximab in Relapsed or Refractory Indolent Non Hodgkin's B-Cell Lymphoma

Second quarter 2021 earnings released: EPS JP¥22.62 (vs JP¥25.98 in 2Q 2020)

Kyowa Kirin Co., Ltd. Announces EU Approval for the Self-administration of CRYSVITA® (burosumab) to Treat X-Linked Hypophosphataemia (XLH)

Upcoming dividend of JP¥23.00 per share

MEI Pharma and Kyowa Kirin to Present Clinical Data from Ongoing Studies Evaluating Zandelisib for Lymphoma at the 16th International Conference on Malignant Lymphoma Virtual Scientific Program

MEI Pharma and Kyowa Kirin Announce First Patient with Marginal Zone Lymphoma Dosed in Expanded Global Phase 2 TIDAL Study Evaluating Zandelisib

MEI Pharma, Inc. and Kyowa Kirin Announce New Clinical Data on Zandelisib At American Society of Clinical Oncology Annual Meeting 2021

財務の健全性基準チェック /66